Abstract:Lung adenocarcinoma (LUAD) with concurrent oncogenic KRAS and STK11 loss-of-function mutations define an aggressive subtype characterized, in part, by increased metastasis. Loss of STK11, a tumor suppressor and nutrient sensor, leads to dysregulation of many critical cellular processes, including metabolism. As such, STK11 null cancers are "glutamine addicted" to support proliferative properties and the tumor microenvironment therefore becomes glutamine depleted. We hypothesize that conditions of glutamine stress promote metastatic potential in STK11 null KRAS-driven LUAD due to metabolic rewiring. To test this hypothesis, we utilized a cell culture model of KRAS-driven LUAD cell lines and corresponding STK11 knockout cell lines (∆STK11). Parental and ∆STK11 cells underwent the Seahorse mitochondrial stress test in full and glutamine-deficient media to obtain parameters of mitochondrial respiration at baseline and under conditions reflective of the tumor microenvironment, respectively. At baseline, ∆STK11 cells had a hypermetabolic phenotype associated with enhanced glutamine utilization. Deprivation of glutamine resulted in decreased mitochondrial respiration along with a significant increase in live, detached ∆STK11 cells compared to the parental line. Upon further examination, the detached ∆STK11 cells maintained the ability to re-adhere and proliferate in full media while the detached parental cells did not. Additionally, expression of pro-survival, anti-apoptotic and EMT markers in ∆STK11 cells were increased upon glutamine deprivation. To determine the mechanism(s) underlying this pro-metastatic phenotype, we employed heavy nitrogen labeling which revealed an upregulation of the hexosamine biosynthetic pathway (HBP). The HBP is an offshoot of glycolysis that serves as a central hub to regulate many cancer fitness pathways via O-GlcNAcylation; the addition of a GlcNAc moiety to serine/threonine residues of target proteins. Further assessment of O-GlcNAcylation levels via western and far western blot analysis revealed that parental cells had decreasing HBP flux concordant with decreasing glutamine concentration while ∆STK11 cells, conversely, had enhanced HBP flux upon decreasing glutamine availability. These observations suggest ∆STK11 cells utilize the HBP as a protective shunt under decreased glutamine availability. We are currently characterizing the invasive potential and anchorage-independence of parental and ∆STK11 LUAD cells upon glutamine deprivation. Future studies aim to establish the impact of HBP perturbation, both genetically and pharmacologically, on the described measures of metastatic potential. Overall, this work reveals novel insight into the molecular mechanisms altered downstream of STK11 loss that link glutamine metabolism with metastatic properties in KRAS-driven LUAD. Citation Format: Shannon Prior, Logan Sands, Sean Lenahan, Hailey Sarausky, Melissa Scheiber, David Seward, Paula Deming. Metabolic rewiring promotes metastatic potential upon glutamine deprivation in STK11 null KRAS-driven lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1791.

NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence <i>via</i> the induction of ASCT2

Tumor Suppressor NDRG2 Inhibits Glycolysis and Glutaminolysis in Colorectal Cancer Cells by Repressing C-Myc Expression

NDRG2 Inhibits Pyruvate Carboxylase-Mediated Anaplerosis and Combines with Glutamine Blockade to Inhibit the Proliferation of Glioma Cells.

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

NDRG2 overexpression suppresses hepatoma cells survival during metabolic stress through disturbing the activation of fatty acid oxidation

Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial–mesenchymal transition in drug-resistant lung cancer

ASCT2 Regulates Fatty Acid Metabolism to Trigger Glutamine Addiction in Basal-like Breast Cancer

ATF4 and N-Myc Coordinate Glutamine Metabolism in MYCN-amplified Neuroblastoma Cells Through ASCT2 Activation.

Role Of Glutamine In Cancer Growth, Invasion And Progression: Therapeutic Modulation Of Glutamine Pathway

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer

N-Myc Promotes Glutamine Anaplerosis And Aggressive Tumor Progression Through Direct Gls2 Activation

Abstract 1791: Metabolic rewiring promotes metastatic potential upon glutamine deprivation in STK11 null KRAS-driven lung adenocarcinoma

Epigenetic Silencing of Microrna-137 Enhances ASCT2 Expression and Tumor Glutamine Metabolism.

Metabolic reprogramming of glutamine involved in tumorigenesis, multidrug resistance and tumor immunity

The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma

ASCT2 (Slc1a5)-Dependent Glutamine Uptake is Involved in the Progression of Head and Neck Squamous Cell Carcinoma

NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade

Abstract 1208: Glutamine Modulates Cellular NAD+/NADH Homeostasis Thereby Regulating Cancer Metastasis, Drug Sensitivity in Cancer Cells

Abstract B05: N-Myc Downstream Regulated Gene 2 is a Novel Regulator of Lipid Metabolism and Ubiquitin-Proteasome System in Cancer

Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells

Colorectal Cancer Cell Differentiation is Dependent on the Repression of Aerobic Glycolysis by NDRG2-TXNIP Axis